The United Nations estimates that over 40 million people are currently infected with HIV-1. Each day approximately 16 000 new infections and half as many deaths occur as a result of AIDS. One of the most substantial challenges to the design of an effective global HIV-1 vaccine is virus variability. As a result of an error-prone reverse transcriptase and lack of polymerase-related proof-reading function, heterogeneity occurs throughout the HIV-1 viral genome. Mutations affect all viral proteins including envelope, the target of neutralizing antibody [1] . Our current goal is to address HIV-1 diversity by the design and testing of a multienvelope vaccine that includes recombinant DNA, vaccinia virus, and protein vectors. As an initial step in this process, we have produced a purified recombinant envelope protein of subtype D and entered this vaccine into a phase I clinical trial at St Jude Children's Research Hospital (SJCRH) in Memphis, Tennessee, USA.
To produce EnvPro, recombinant Chinese hamster ovary cells expressing UG92005 gp140 envelope gene (GenBank accession no. AF338704) were grown under current good manufacturing practice conditions for the collection of supernatants and isolation of soluble protein.
Envelope was purified by affinity chromatography and formulated with alum (Reheis, Berkeley Heights, New Jersey, USA). Single vaccine doses comprised 100 mg envelope protein mixed with 500 mg alum and were administered by the intramuscular route.
This study was designed as a single-center trial employing standard criteria (as defined in the HVTN Table for Grading Severity of Adverse Experiences, 18 September 2002) , to evaluate the tolerability and safety of intramuscular EnvPro. The study was approved by the internal regulatory committees of SJCRH (including the Institutional Review Board) and an investigational new drug application was approved by the United States Food and Drug Administration. Signed informed consent was received from all study participants. The study enrolled nine participants (four women and five men, average age 38.2 years) and evaluated each for vaccine tolerability, focusing particularly on the 28 days after vaccination. Participants were enrolled serially, one every 28 days (as requested by the SJCRH Institutional Review Board), such that only one participant was being observed for tolerability and safety at any given time. Two doses of vaccine were administered 8 weeks apart. This dosing schedule was based on our preclinical studies and on studies of other purified protein vaccines [2] .
Inclusion criteria required study participants to be healthy adults (> 18 years) and HIV-1 negative with normal complete blood counts, CD4 T-cell counts (! 400 cells/ ml), aspartate aminotransferase, alanine aminotransferase, serum creatinine, sodium, potassium and chloride and creatine phosphokinase. Prospective volunteers were excluded if they had a history of immunosuppressive illness, chronic illness, or the use of any immunosuppressive medications, had received live attenuated vaccines within 60 days of study enrollment, had received experimental agents within 30 days of study enrollment, had received blood products or immunoglobulin in the past 6 months, were allergic to gentamicin, or were pregnant or nursing at the time of vaccination.
All candidates enrolled in this study received counselling for safe sexual practices. Recruitment and compliance were excellent.
As demonstrated in Fig. 1(a) , EnvPro was uniformly well tolerated and participants did not develop laboratory abnormalities. Adverse events that were considered possibly, probably or definitely vaccine related were grade 1 only and included pain, warmth or swelling at the injection sight, headache, fatigue, malaise, myalgia, and nausea. No unexpected vaccine-related adverse events were noted. Adverse events were largely related to the intramuscular inoculation itself (e.g. tenderness, mild swelling or perceived warmth at the site of inoculation) or systemic manifestations such as general malaise, headache, fatigue or nausea. Four of the nine study participants reported no adverse events considered to be related to vaccination.
Immune responses were examined using the Abbott clinical enzyme-linked immunosorbent assay [HIVAB HIV-1/HIV-2 (recombinant DNA) enzyme immunoassay; Abbott Laboratories, Abbott Park, Illinois, USA]. Results are shown for each of the nine volunteers in Fig. 1(b) . Each volunteer exhibited a classic immune response in that little activity was seen after the priming immunization, but assays scored positively for all volunteers after the booster immunization. This frequency of positive antibody responses in a standard serological test (100%) exceeded that observed in several other studies of HIV-1 protein vaccines [3] , highlighting the potency of the gp140/alum formulation. In several participants responses waned, but in two volunteers (participants 509 and 511), [4, 5] .
As expected based on preclinical studies, EnvPro vaccinations did not have the potency of prime-boost multivectored regimens [6, 7] ; neutralizing antibody or T-cell responses of high magnitude were not identified (data not shown).
Future plans are to combine EnvPro with DNA and vaccinia virus recombinant vectors in a prime-boost clinical protocol [6, [8] [9] [10] . As with EnvPro, our DNA and vaccinia virus vectors [11] have also been tested in individual phase I safety trials and elicited no unexpected vaccine-related adverse events. Our preclinical studies indicate that the prime-boost regimen will elicit responses of greater magnitude, breadth and durability.
In conclusion, we describe the safety and immunogenicity of the first subtype D HIV-1 gp140 envelope protein vaccine to be tested in a phase I clinical trial. These results are promising and encourage the advancement of EnvPro to a trial that combines multiple vectors and multiple envelopes. A clinical trial with a multienvelope vaccine (utilizing recombinant DNA, vaccinia virus and purified protein; D-V-P) has now been approved by the United States Food and Drug Administration. Results from the study described in this report suggest that virtually every volunteer will respond to the D-V-P combination vaccine. On the basis of results from small and large animal studies [12] , broad, durable and robust B and T-cell immune activities are expected when EnvPro is tested as part of this multivector, multienvelope vaccine study in humans. Thai patients enrolled in STACCATO with HIV/ hepatitis B virus (HBV) co-infection and tenofovir/ emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.
The management of chronic hepatitis B virus (HBV)/ HIV co-infection has to consider both infections. Scheduled treatment interruption (STI) of HIV therapy potentially reduces side effects and costs and increases comfort and quality of life by decreasing overall drug exposure. A reason for concern in patients with HIV/ HBV co-infection undergoing STI is the occurrence of severe and in some cases lethal acute hepatitis after interrupting HBV treatment, described in 19-50% of patients [1] [2] [3] [4] [5] . Tenofovir and emtricitabine have shown potent and sustained activity against hepatitis B [6] [7] [8] [9] [10] [11] [12] , and the combination of both drugs may be even more beneficial. Both drugs are active against HIV and are an appealing option to treat patients with HBV/HIV coinfection. STACCATO was a large multinational trial investigating CD4 cell count-guided STI. In Thailand, where HIV/HBV co-infection is frequent [13] , patients enrolled in the STACCATO study were treated with antiretroviral therapy (ART) containing tenofovir/ emtricitabine. This offered a unique opportunity to study the effect of this drug combination on patients with HIV/HBV co-infection, and their reaction to treatment interruptions.
STACCATO was a randomized trial of continuous versus CD4 cell count-guided treatment with a threshold CD4 cell count of 350 cells/ml [14] .
Thai patients with HIV/HBV co-infection who started tenofovir/emtricitabine-containing ART underwent repeated plasma sampling for liver enzymes and hepatitis B viral load on weeks 4, 8, 12 and every 12 weeks thereafter up to the end of STACCATO. A complete hepatitis B serology was performed at the initiation of tenofovir/emtricitabine and at week 48. HIV viral load and CD4 cell counts were assessed according to the STACCATO protocol [14] . Patients off therapy who had transaminases five or more times the upper limit or normal (ULN) or bilirubinemia more than 2.5 times the ULN were treated again immediately with tenofovir/ emtricitabine-containing ART. The study was performed in accordance with the approval of the local ethical committee.
For HBV, viral load and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) time-weighted average changes were calculated from baseline to week 48. An intention-to-treat approach (including all subjects) was used. Last values were carried forward when data were missing. Average change in time-weighted HBV viral load, AST and ALT were compared using a paired t-test. Statistical analyses were performed using STATA version 8.2 (STATA Corp., College Station, Texas, USA). Statistical significance was taken as a two-sided P value of less than 0.05.
The HBV viral load in serum was measured using the commercial quantitative polymerase chain reaction assay the Cobas Amplicor Monitor Test (Roche Diagnostic Systems, Inc., Branchburg, New Jersey, USA). For serological testing the commercial enzyme-linked immunosorbent assay Mini VIDAS Instrument was used (Biomerieux Co., Marcy l'Etoile, France).
Among the 362 Thai patients included in the STACCATO trial, 16 had a detectable hepatitis B surface antigen and a negative hepatits C serology when tenofovir/emtricitabine was started. Baseline characteristics are shown in Table 1 . Six patients were treated within the continuous arm, 10 in the CD4 cell count-guided arm: six of them underwent one to two (mean 1.3) on-off cycles. Transaminases at baseline were normal in eight patients; six patients had an elevation of twice the ULN, two patients an elevation of more than three times the ULN. Seven patients had a positive hepatitis Be (HBe) antigen. Median follow-up time was 69 weeks (48-96). At week 48 one patient in the continuation arm became negative for HBe antigen and developed HBe antibodies, one lost his hepatitis B surface (HBs) antigen but did not develop HBs antibodies. This patient had HBV viraemia below the detection limit at inclusion. The combination of tenofovir/emtricitabine suppressed HBV replication below the detection limit in 15 of 16 patients after 4-24 weeks. One patient interrupted therapy when HBV viraemia was 4062 copies/ml, dropping from 10 8 after 24 weeks. Continuous treatment reduced AST (À17.8, 47.5) and ALT (À31.3, 47.8; P ¼ 0.2). After STI, the median increase in log HBV load was 2.52 (0.49-4.70), , and AST 7 (À11-350). Immediate reinitiation of therapy was necessary because of a flare of hepatitis with AST reaching 408 U/l, ALT 218 U/l, bilirubin 23.1 mmol/l, and viral load log 7.61 copies/ml. In the other patients ALT The combination of tenofovir/emtricitabine completely suppressed HBV replication in 15 of the 16 patients. In one patient, treatment was interrupted before HBV viraemia was below the detection limit. Complete suppression would probably have been achieved without STI. The control of HBV lasted until the end of followup (maximum 96 weeks). The excellent virological response to tenofovir/emtricitabine-based ART was paralleled by a decrease in transaminases. As most patients had normal transaminases at baseline, this decrease did not reach statistical significance. Patients in the STI arm had a worse control of HBV and consecutively higher transaminase levels. This is problematical for various reasons [15] [16] [17] . Treatment interruptions may compromise the outcome by permitting HBV replication. After 48 weeks one patient seroconverted from HBe antigen to HBe antibodies, one other patient lost his HBs antigen (core only). Both were on continuous treatment. So far HBe seroconverison has been described exclusively in HIV-infected patients with active ART in the range of 12-25% [2] [3] [4] [5] 16] . Most elevations of liver enzymes were asymptomatic, not severe, and all responded well to retreatment. One patient, however, required immediate intervention because of a flare of hepatitis as defined by the protocol. Although manageable with tenofovir/ emtricitabine-containing ART such an event is alarming.
Tenofovir/emtricitabine-containing ART is highly effective in controlling both chronic HBVand HIV infections. It is an ideal combination to treat HIV/HBV-co-infected patients and has been recommended previously [12] .
Treatment interruptions in HBV/HIV-co-infected patients may induce progression and flares of hepatitis B even with careful monitoring. This is in addition to potential disadvantages regarding HIV infection [17, 18] . ART with drugs active against HBV in HIV/HBVco-infected patients should not be interrupted.
The Staccato Hepatitis B Study Group
The A study of 312 untreated and 303 HAART-initiating patients to determine whether HAART is related to sexual risk taking in Cô te d'Ivoire. At enrolment, unprotected sex was higher among untreated patients (P U 0.014). During follow-up, risk taking was similar (P U 0.484) as a result of an increase in unprotected sex among treated patients (from 20.4 to 30.1%, P < 0.0001) and stability among untreated patients (from 27.0 to 28.8%, P U 0.301). HAART appeared to be associated with sexual risk taking.
HAART has been found to be associated with changes towards unsafe sex in some industrialized countries [1] [2] [3] [4] [5] [6] . This study aimed to see whether HAART was related to such a behaviour change in Côte d'Ivoire, sub-Saharan Africa.
From February to September 2005, we enrolled two groups of HIV-1-infected patients newly attending the largest Ivorian HIV/AIDS day hospital (Unité de Soins Ambulatoires et de Conseils). Group I included consecutive patients (number ! 300) who received HAART after the initial consultation, whereas group II included a similar number of consecutive patients who did not receive HAART (remained untreated). The patients were followed for 6 months. A questionnaire was administered, at inclusion and 6 months thereafter.
Patients were asked about their sexual practices during the 6 months before visit 1 ('period 1') and visit 2 ('period 2'): the number of regular/casual sexual partners and condom use (any sexual act). Condom use was assessed on a fourlevel scale: never; less than half of the time; half of the time or more; always. Unsafe sex was defined as at least one unprotected sex (first three levels of the scale) with any sexual partner. Information was also collected on the potential predictors of unsafe sex. Untreated patients received the guarantee that they would receive HAART if their condition (clinical/biological) worsened during follow-up.
After univariate analyses, variables with P values of 0.10 or less were included in a multivariate model containing three principal independent variables: the 'period'; the 'group'; and their interaction term. Interaction terms between the independent predictors of unsafe sex and both the 'group' and the 'period' were examined. Variables with P values less than 5% (independent predictors) and less than 15% (interaction terms) were kept in the final model. The model was adjusted for sex, the presence of a regular sexual partner and sexual abstinence at baseline. Generalized estimating equations with repeated measures were used.
Overall, 615 patients were recruited (303 in group I and 312 in group II). The median age was 35 years. A total of 139 patients (22.6%) reported that their last sexual partner was HIV negative. For 202 patients (32.8%), that status was unknown. In each group, approximately one-third of the patients have disclosed their HIV status to a close person, and a similar proportion reported sexual abstinence during period 1. The median number of sexual partners was one regardless of the group and the period (data not shown). Figure 1 presents the proportion of unsafe sex by group and by period. During period 1, unprotected sex was significantly higher in group II (P ¼ 0.014). During period 2, patients from both groups reported a similar risk (P ¼ 0.484). The difference between groups II and I decreased from þ6.6% during period 1 to À1.3% during period 2 (P ¼ 0.005). This was related to a significant increase in unprotected sex among treated patients (P < 0.0001) and stability among untreated patients (P ¼ 0.301). Three factors were independently associated with unprotected sex in the presence of the three principal variables: in comparison with Centers for Disease Control and Prevention category C, it was more risky to belong to category A [relative risk (RR) 1.94; 95% confidence interval (CI) 1.40-2.67] or B (RR 1.84; 95% CI 1.34-2.54); younger age (< 40 years, RR 1.40; 95% CI 1.17-1.67) and alcohol consumption (RR 1.16; 95% CI 1.02-1.31) were also associated with unsafe sex.
The increase in risk taking among treated patients is consistent with the clinical improvements and other positive outcomes found to be associated with HAART [7] [8] [9] [10] . In addition, the significant decrease in the intergroup gap over time highlighted an increasing adverse effect of HAART on sexual behaviour. These results are strengthened by the fact that, in our study, patients with less advanced infection (Centers for Disease Control and Prevention clinical stages A/B) reported unsafe sex more often than those with severe symptoms (stage C). Observed changes in unprotected sex among treated patients were unlikely to be attributable to those who became sexually active because we adjusted for sexual abstinence at baseline. The increase in risk taking among the treated patients was, partly, initially limited to steady sexual partners: the median number of partners did not increase during follow-up. This increase was observed after a short period of follow-up (6 months). One may hypothesize that if the positive outcomes become more evident and stable with time, treated patients could start seeking for unprotected sex with casual or serodiscordant partners. This concern is supported by the fact that more than half of our treated patients reported that their last sexual partner was HIV negative or of unknown status. Our results are consistent with previous findings showing an increase in unprotected sex after the introduction of HAART in developed countries [1, 2] . Unprotected heterosexual contacts have also been found to be frequent [11] and specifically related to new HIV seroconversions [12] in Europe. Our results are not consistent with those of a meta-analysis that found that the prevalence of unprotected sex was not higher among HIV-infected individuals receiving HAART [13] . The difference with our study (heterosexual context) may be caused by cultural specificities, but to our knowledge, only one prospective quantitative study on this subject has been conducted in sub-Saharan Africa [14] . The latter was conducted in parallel with preventive interventions (contrary to our study) and did not find an increase in risk-taking after treatment initiation. This underscores the importance of coupling HAART along with counselling programmes aimed at encouraging patients to adopt and maintain safer sexual practices [15] . As previously demonstrated, younger age [16] and alcohol consumption [11] were also associated with unsafe sex in our study.
Social desirability could have induced an underestimation of risk taking, but there is no reason for a differential report between groups. The patients were enrolled from a single clinic, which may induce a selection bias, but this clinic is the largest HIV/AIDS day hospital in Côte d'Ivoire and it receives patients from all over the country.
Our study supports a causal relationship between the use of HAART and an increase in sexual risk taking among HIV-1-infected patients in Côte d'Ivoire. Given the scale-up of antiretroviral therapy in sub-Saharan Africa, more research is needed to examine this issue in more depth. [5] . CRF07_BC accounts for 98% of the infections among IDU in Taiwan [4] .
To estimate the timescale of CRF07_BC spread in mainland China (Xinjiang) and in Taiwan, we performed phylogenetic and Bayesian coalescent analyses on env sequences obtained from GenBank. The CRF07_BC env sequences used in this study are from Xinjiang province, China (n ¼ 4; sampled in 1997-1998), and from three cities in Taiwan; in particular, Tainan (southern; n ¼ 19), Nantou (central; n ¼ 8) and Taipei (northern; n ¼ 8), all sampled in 2004 (accession numbers EF078077-EF078079, EF078082-EF078105 and EF078107-EF078114). As shown in Fig. 1a , the CRF07_BC sequences group into three distinct phylogenetic clusters, denoted Xinjiang (China), Tainan (southern Taiwan) and Nantou-Taipei (central and northern Taiwan). Using the molecular clock approach implemented in BEAST v1.4 [6] , we estimated the rate of evolution of the hypervariable region-stripped env gene (HXB2 7077-7665 nt) from an independent dataset of 41 HIV-1 subtype C strains with known sampling dates that ranged from 1989 to 2005. The evolutionary rate estimate obtained (4.7-5.0 Â 10 À3 substitutions per site per year) was then incorporated as a prior probability distribution in the analysis of the CRF07_BC sequences [7] . A Bayesian Markov chain Monte Carlo method was used to estimate the dates of the most recent common ancestors (MRCA) of CRF07_BC in Xinjiang and Taiwan under various nucleotide substitution and evolutionary models. As illustrated in Fig. 1b, the , respectively. The evolutionary and statistical assumptions used have almost no effect on the estimated dates (Fig. 1b) .
This study indicates that CRF07_BC was introduced into the IDU population in Xinjiang in the early to mid 1990s (1992) (1993) (1994) (1995) . The strain also spread into IDU in southern Taiwan (Fig. 1c) , suggesting that CRF07_BC may have been present among IDU for a year or two in each region before the epidemic spread and subsequent detection of the infection. It is most likely that both the Xinjiang and Taiwan outbreaks trace their origins back to Yunnan province, thought to be the geographical origin of CRF07_BC [2, 3] . We note, however, that MRCA dates can also be more recent than the date of outbreak discovery, either because extant virus diversity has been incompletely sampled, or because the founding lineages of the outbreak have since gone extinct [8, 9] . These results illustrate the history of the regional and international spread of HIV-1 CRF07_BC in east Asia.
